| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
High PD-L1 expression as a negative prognostic factor in stage III but not in stage II gastric cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Hui-Min Zhang, Feng-Ping Li, Heng-Yi Zhang, Xin-Ru Liu, Xin-Hua Chen, Hua-Yuan Liang, Xiao Yan, Qing Xie, Rou Zhong, Min Lai, Xue-Feng Zhong, Hao Liu and Li-Ying Zhao |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| the Noncommunicable Chronic Diseases-National Science and Technology Major Project |
2023ZD0501500 |
|
| Corresponding Author |
Li-Ying Zhao, Assistant Professor, Department of General Surgery and Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, Department of General Surgery, Nanfang Hospital, Southern Medical University, No. 1838 Guangzhou Ave. North, Guangzhou 510515, Guangdong Province, China., Guangzhou 510515, Guangdong Province, China. zlyblue11@163.com |
| Key Words |
Survival; Prognosis; Locally advanced gastric cancer; Combined positive score; Programmed death ligand-1 |
| Core Tip |
This retrospective cohort study revealed that high programmed death ligand-1 (PD-L1) expression was an independent adverse prognostic factor for disease-free and overall survival in pathological stage III gastric or gastroesophageal junction cancer (G/GEJC). However, in pathological stage II G/GEJC, patients with high PD-L1 expression tended to have better survival despite the lack of statistical significance. These findings align with the subgroup analysis of the KEYNOTE-585 trial, which indicated the clinical benefit of anti-programmed death 1 therapy in stage III G/GEJC but not in stage II. This study provides theoretical support for designing future perioperative precision immunotherapy trials in G/GEJC. |
| Publish Date |
2026-02-11 07:19 |
| Citation |
Zhang HM, Li FP, Zhang HY, Liu XR, Chen XH, Liang HY, Yan X, Xie Q, Zhong R, Lai M, Zhong XF, Liu H, Zhao LY. High PD-L1 expression as a negative prognostic factor in stage III but not in stage II gastric cancer. World J Gastroenterol 2026; 32(8): 115333 |
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i8/115333.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v32.i8.115333 |
